Post Profile






Nintedanib improves progression-free survival but not overall survival in phase III trial of metastatic colorectal cancer

Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial.
read more

share

Related Posts


Metastatic Colorectal Cancer - Regorafenib (BAY 73-4506) Improves Overall Survival

Health : Medical News Today

According to an announcement made by Bayer HealthCare Pharmaceuticals, the Phase III trial of its investigational compound regorafenib (BAY 73-4506) to treat individuals with metastatic colorectal cancer (mCRC) whose disease progres...

Successful Trial Shows Drug Improves Survival Of Colorectal Cancer Patients

Health : Medical News Today

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented at the ...

Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The first phase III study of PD-L1 inhibitor  atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.

Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.

Comments


Copyright © 2016 Regator, LLC